Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | NOX1 | Q9Y5S8 | 1/20 | 0.35 |
| ▸ | CA12 | O43570 | 3/20 | 0.35 |
| ▸ | CA1 | P00915 | 3/20 | 0.35 |
| ▸ | CA2 | P00918 | 3/20 | 0.35 |
| ▸ | CA9 | Q16790 | 3/20 | 0.35 |
| ▸ | PDE7A | Q13946 | 1/20 | 0.35 |
| ▸ | PDE7B | Q9NP56 | 1/20 | 0.35 |
| ▸ | CA4 | P22748 | 1/20 | 0.35 |
| ▸ | CA7 | P43166 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18729469 | 0.77 | KMT2A (0.38) | GAAMAPTMEN1KMT2ANOX1 | |
| SCHEMBL11720850 | 0.75 | CA12 (0.38) | CA12CA9 | |
| SCHEMBL7560150 | 0.72 | — | — | |
| SCHEMBL26180532 | 0.72 | CA12 (0.41) | CA12CA1CA2CA9CA4 | |
| SCHEMBL10577326 | 0.69 | GAA (0.40) | GAAMAPTMEN1KMT2ANOX1 | |
| SCHEMBL25929516 | 0.69 | TYR (0.32) | GAA | |
| SCHEMBL25926848 | 0.69 | CA12 (0.39) | GAAMAPTMEN1KMT2ACA12 | |
| SCHEMBL3541084 | 0.64 | MEN1 (0.34) | GAAMAPTMEN1KMT2ANOX1 | |
| SCHEMBL2520640 | 0.64 | MEN1 (0.34) | GAAMAPTMEN1KMT2ANOX1 | |
| SCHEMBL620329 | 0.64 | CA12 (0.37) | GAAMAPTMEN1KMT2ANOX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-104628674-B | 4-hydroxy-3-acyl-1-alkyl-2,1-benzothiazine-2,2-dioxide derivative and application thereof | 南开大学 | 2017-02-01 | — | — | CN | claimed |
| US-20250171433-A1 | A1H-BENZO[C][1,2]THIADIAZINE-2,2-DIOXIDES BEARING HETEROCYCLIC LINKERS AS SELECTIVE HISTONE DEACETYLASE 6 INHIBITORS | GEORGETOWN UNIVERSITY (US) | 2025-05-29 | — | — | US | disclosed |
| EP-4475845-A1 | A1H-BENZO[C][1,2]THIADIAZINE-2,2-DIOXIDES BEARING HETEROCYCLIC LINKERS AS SELECTIVE HISTONE DEACETYLASE 6 INHIBITORS | Georgetown University (US) | 2024-12-18 | — | — | EP | disclosed |
| CN-118973573-A | 1H-benzo [ c ] [1,2] thiadiazine-2, 2-dioxides carrying a heterocyclic linker as selective histone deacetylase 6 inhibitors | 乔治城大学 | 2024-11-15 | — | — | CN | disclosed |
| WO-2023154758-A1 | A1H-BENZO[C][1,2]THIADIAZINE-2,2-DIOXIDES BEARING HETEROCYCLIC LINKERS AS SELECTIVE HISTONE DEACETYLASE 6 INHIBITORS | GEORGETOWN UNIVERSITY (US) | 2023-08-17 | — | — | WO | disclosed |
| EP-3489233-B1 | INDOLE DERIVATIVE USED AS CRTH2 INHIBITOR | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO LTD (CN) | 2022-01-12 | — | — | EP | disclosed |
| US-20210052621-A1 | METHODS FOR TREATING FLAVIVIRUSES AND ZIKA INFECTIONS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA, A CALIFORNIA CORPORATION (US) | 2021-02-25 | — | — | US | disclosed |
| US-10383880-B2 | Carbazole-containing sulfonamides as cryptochrome modulators | Synchronicity (US) | 2019-08-20 | — | — | US | disclosed |
| US-10383880-B2 | Carbazole-containing sulfonamides as cryptochrome modulators | Synchronicity (US) | 2019-08-20 | — | — | US | disclosed |
| EP-3489233-A1 | INDOLE DERIVATIVE USED AS CRTH2 INHIBITOR | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (CN) | 2019-05-29 | — | — | EP | disclosed |
| WO-2008154221-A2 | MODULATION OF CHEMOSENSORY RECEPTORS AND LIGANDS ASSOCIATED THEREWITH | SENOMYX, INC. (US) | 2008-12-18 | — | — | WO | disclosed |
| US-20080171737-A1 | CYCLIC SULFONAMIDE DERIVATIVES AND METHODS OF THEIR USE | WYETH (US) | 2008-07-17 | — | — | US | disclosed |
| US-20080171737-A1 | CYCLIC SULFONAMIDE DERIVATIVES AND METHODS OF THEIR USE | WYETH (US) | 2008-07-17 | — | — | US | disclosed |
| US-20080171737-A1 | CYCLIC SULFONAMIDE DERIVATIVES AND METHODS OF THEIR USE | WYETH (US) | 2008-07-17 | — | — | US | disclosed |
| WO-2008073956-A2 | CYCLIC SULFONAMIDE DERIVATIVES AND METHODS OF THEIR USE | WYETH (US) | 2008-06-19 | — | — | WO | disclosed |
| WO-2008073956-A2 | CYCLIC SULFONAMIDE DERIVATIVES AND METHODS OF THEIR USE | WYETH (US) | 2008-06-19 | — | — | WO | disclosed |
| US-4960870-A | DYEING WOOL, POLYAMIDES; FIBER REACTIVE DYES | CIBA-GEIGY CORPORATION (US) | 1990-10-02 | — | — | US | disclosed |
| US-4675046-A | HERBICIDES, PLANT GROWTH REGULATORS | CIBA-GEIGY CORPORATION (US) | 1987-06-23 | — | — | US | disclosed |
| US-4675417-A | HERBICIDE CHEMICAL INTERMEDIATES | CIBA-GEIGY CORPORATION (US) | 1987-06-23 | — | — | US | disclosed |
| US-4589911-A | Fused N-phenylsulfonyl-N-triazinylureas | CIBA-GEIGY CORPORATION (US) | 1986-05-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250171433-A1 | A1H-BENZO[C][1,2]THIADIAZINE-2,2-DIOXIDES BEARING HETEROCYCLIC LINKERS AS SELECTIVE HISTONE DEACETYLASE 6 INHIBITORS | HDAC1, HDAC6, HDAC11 | GAA 1347/4885MAPT 196/4885MEN1 1488/4885 |
| US-10383880-B2 | Carbazole-containing sulfonamides as cryptochrome modulators | CRY1, CRY2, CRYAB | GAA 2188/4885MAPT 3146/4885MEN1 773/4885 |
| US-20080171737-A1 | CYCLIC SULFONAMIDE DERIVATIVES AND METHODS OF THEIR USE | SLC6A4, SLC6A2, SLC6A3 | GAA 452/4885MAPT 998/4885MEN1 3031/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.